Andrés Méndez-Lucas

Andrés Méndez-Lucas

Auto-generated profile, based on publicly available information

Andrés Méndez-Lucas

Physiological Sciences Department, University of Barcelona, Campus de Bellvitge, L’Hospitalet de Llobregat, Spain

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2019 in Nature
Verified
Journal Article
Closed access
PDF file
KVKim Vriens
Kim Vriens
SCStefan Christen
Stefan Christen
SPSweta Parik
Sweta Parik
DBDorien Broekaert
Dorien Broekaert
KYKazuaki Yoshinaga
Kazuaki Yoshinaga
SFSarah-Maria Fendt
Sarah-Maria Fendt

1 June 2012 in Journal of Lipid Research
Verified
Journal Article
Open access
PDF file
SSSanthosh Satapati
Santhosh Satapati
NSNishanth E. Sunny
Nishanth E. Sunny
BKBlanka Kucejova
Blanka Kucejova
XFXiaorong Fu
Xiaorong Fu
THTian Teng He
Tian Teng He
SBShawn Burgess
Shawn Burgess
The manner in which insulin resistance impinges on hepatic mitochondrial function is complex. Although liver insulin resistance is associated with respiratory dysfunction, the effect on fat oxidation remains controversial, and biosynthetic pathways that traverse mitochondria are actually increased. The tricarboxylic acid (TCA) cycle is the site of terminal fat oxidation, chief source of electrons for respiration, and a metabolic progenitor of gluconeogenesis. Therefore, we tested whether insulin resistance promotes hepatic TCA cycle flux in mice progressing to insulin resistance and fatty liver on a high-fat diet (HFD) for 32 weeks using standard biomolecular and in vivo 2H/13C tracer methods. Relative mitochondrial content increased, but respiratory efficiency declined by 32 weeks of HFD. Fasting ketogenesis became unresponsive to feeding or insulin clamp, indicating blunted but constitutively active mitochondrial β-oxidation. Impaired insulin signaling was marked by elevated in vivo gluconeogenesis and anaplerotic and oxidative TCA cycle flux. The induction of TCA cycle function corresponded to the development of mitochondrial respiratory dysfunction, hepatic oxidative stress, and inflammation. Thus, the hepatic TCA cycle appears to enable mitochondrial dysfunction during insulin resistance by increasing electron deposition into an inefficient respiratory chain prone to reactive oxygen species production and by providing mitochondria-derived substrate for elevated gluconeogenesis.

1 August 2014 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
AMAndrés Méndez-Lucas
Andrés Méndez-Lucas
PHPetra Hyroššová
Petra Hyroššová
LNLaura Novellasdemunt
Laura Novellasdemunt
FVFrancesc Viñals
Francesc Viñals
JPJosé Carlos Perales
José Carlos Perales
Mitochondrial phosphoenolpyruvate carboxykinase (PEPCK-M), encoded by the nuclear PCK2 gene, links TCA cycle intermediates and glycolytic pools through the conversion of mitochondrial oxaloacetate into phosphoenolpyruvate. In the liver PEPCK-M adjoins its profusely studied cytosolic isoform (PEPCK-C) potentiating gluconeogenesis and TCA flux. However, PEPCK-M is present in a variety of non-gluconeogenic tissues, including tumors of several origins. Despite its potential relevance to cancer metabolism, the mechanisms responsible for PCK2 gene regulation have not been elucidated. The present study demonstrates PEPCK-M overexpression in tumorigenic cells as well as the mechanism for the modulation of PCK2 abundance under several stress conditions. Amino acid limitation and ER stress inducers, conditions that activate the amino acid response (AAR) and the unfolded protein response (UPR), stimulate PCK2 gene transcription. Both the AAR and UPR lead to increased synthesis of ATF4, which mediates PCK2 transcriptional up-regulation through its binding to a putative ATF/CRE composite site within the PCK2 promoter functioning as an amino acid response element. In addition, activation of the GCN2-eIF2α-ATF4 and PERK-eIF2α-ATF4 signaling pathways are responsible for increased PEPCK-M levels. Finally, PEPCK-M knockdown using either siRNA or shRNA were sufficient to reduce MCF7 mammary carcinoma cell growth and increase cell death under glutamine deprivation or ER stress conditions. Our data demonstrate that this enzyme has a critical role in the survival program initiated upon stress and shed light on an unexpected and important role of mitochondrial PEPCK in cancer metabolism.

21 April 2020 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
AMAndrés Méndez-Lucas
Andrés Méndez-Lucas
WLWei Lin
Wei Lin
PDPaul C. Driscoll
Paul C. Driscoll
NLNathalie Legrave
Nathalie Legrave
LNLaura Novellasdemunt
Laura Novellasdemunt
MYMariia Yuneva
Mariia Yuneva

1 August 2008 in Diabetes
Verified
Journal Article
Open access
AGAlicia G. GómEz-Valadés
Alicia G. GómEz-Valadés
AMAndrés MénDez-Lucas
Andrés MénDez-Lucas
AVAnna Vidal-Alabró
Anna Vidal-Alabró
FBFrancese X. Blasco
Francese X. Blasco
MCMiguel Chillon
Miguel Chillon
JPJosé Carlos Perales
José Carlos Perales
OBJECTIVE—Cytosolic phosphoenolpyruvate carboxykinase (PEPCK-C; encoded by Pck1) catalyzes the first committed step in gluconeogenesis. Extensive evidence demonstrates a direct correlation between PEPCK-C activity and glycemia control. Therefore, we aimed to evaluate the metabolic impact and their underlying mechanisms of knocking down hepatic PEPCK-C in a type 2 diabetic model. RESEARCH DESIGN AND METHODS—PEPCK-C gene targeting was achieved using adenovirus-transduced RNAi. The study assessed several clinical symptoms of diabetes and insulin signaling in peripheral tissues, in addition to changes in gene expression, protein, and metabolites in the liver. Liver bioenergetics was also evaluated. RESULTS—Treatment resulted in reduced PEPCK-C mRNA and protein. After treatment, improved glycemia and insulinemia, lower triglyceride, and higher total and HDL cholesterol were measured. Unsterified fatty acid accumulation was observed in the liver, in the absence of de novo lipogenesis. Despite hepatic lipidosis, treatment resulted in improved insulin signaling in the liver, muscle, and adipose tissue. O2 consumption measurements in isolated hepatocytes demonstrated unaltered mitochondrial function and a consequent increased cellular energy charge. Key regulatory factors (FOXO1, hepatocyte nuclear factor-4α, and peroxisome proliferator–activated receptor-γ coactivator [PGC]-1α) and enzymes (G6Pase) implicated in gluconeogenesis were downregulated after treatment. Finally, the levels of Sirt1, a redox-state sensor that modulates gluconeogenesis through PGC-1α, were diminished. CONCLUSIONS—Our observations indicate that silencing PEPCK-C has direct impact on glycemia control and energy metabolism and provides new insights into the potential significance of the enzyme as a therapeutic target for the treatment of diabetes.

1 July 2013 in Journal of Hepatology
Verified
Journal Article
Closed access
AMAndrés Méndez-Lucas
Andrés Méndez-Lucas
JDJoão André Gonçalves Duarte
João André Gonçalves Duarte
NSNishanth E. Sunny
Nishanth E. Sunny
SSSanthosh Satapati
Santhosh Satapati
THTianTeng He
TianTeng He
JPJosé Carlos Perales
José Carlos Perales